Mexican ranchers struggle to adapt as a tiny parasite ravages their cattle exports to the US
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Rivian Stock Plunges After Brutal Q2 Earnings and Weak Outlook
Aug 6 - Rivian Automotive (NASDAQ:RIVN) dipped more than 3% on Wednesday after posting mixed Q2 results that left Wall Street unimpressed. The EV maker reported a loss of $0.97 per share, missing consensus expectations by $0.32, though revenue came in slightly ahead at $1.30 billion versus the expected $1.27 billion, a 12.5% year-over-year increase. Warning! GuruFocus has detected 5 Warning Signs with RIVN. The revenue beat didn't do much to soften the blow of the wider-than-expected loss, as investors responded with a sell-off that pushed shares down to $12.00 during mid-day trading. Adding to the market's hesitation, the company continues to burn cash aggressively, with negative margins and return on equity weighing heavily on investor sentiment. Analyst ratings remain mixed, with a wide price target range from $12 to $18 and a consensus near $14.30. Insider selling by Rivian's CEO and CFO in recent months also added downward pressure, even as institutional ownership remains strong. While Rivian's long-term vision in EVs and autonomous tech continues to attract attention, the company faces mounting challenges balancing growth and profitability in a capital-intensive space. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
McKesson's (NYSE:MCK) Q2 Sales Top Estimates
Healthcare distributor and services company McKesson (NYSE:MCK) announced better-than-expected revenue in Q2 CY2025, with sales up 23.4% year on year to $97.83 billion. Its non-GAAP profit of $8.26 per share was 1.4% above analysts' consensus estimates. Is now the time to buy McKesson? Find out in our full research report. McKesson (MCK) Q2 CY2025 Highlights: Revenue: $97.83 billion vs analyst estimates of $96.48 billion (23.4% year-on-year growth, 1.4% beat) Adjusted EPS: $8.26 vs analyst estimates of $8.15 (1.4% beat) Management slightly raised its full-year Adjusted EPS guidance to $37.50 at the midpoint Operating Margin: 1.1%, in line with the same quarter last year Free Cash Flow was -$1.11 billion compared to -$1.55 billion in the same quarter last year Market Capitalization: $88.76 billion Company Overview With roots dating back to 1833, making it one of America's oldest continuously operating businesses, McKesson (NYSE:MCK) is a healthcare services company that distributes pharmaceuticals, medical supplies, and provides technology solutions to pharmacies, hospitals, and healthcare providers. Revenue Growth A company's long-term sales performance is one signal of its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Over the last five years, McKesson grew its sales at a decent 10.3% compounded annual growth rate. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. McKesson's annualized revenue growth of 15.3% over the last two years is above its five-year trend, suggesting its demand recently accelerated. We can better understand the company's revenue dynamics by analyzing its most important segment, U.S. Pharmaceutical . Over the last two years, McKesson's U.S. Pharmaceutical revenue averaged 17.6% year-on-year growth. This quarter, McKesson reported robust year-on-year revenue growth of 23.4%, and its $97.83 billion of revenue topped Wall Street estimates by 1.4%. Looking ahead, sell-side analysts expect revenue to grow 10% over the next 12 months, a deceleration versus the last two years. We still think its growth trajectory is attractive given its scale and implies the market is forecasting success for its products and services. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Operating Margin McKesson was roughly breakeven when averaging the last five years of quarterly operating profits, lousy for a healthcare business. On the plus side, McKesson's operating margin rose by 3.3 percentage points over the last five years, as its sales growth gave it operating leverage. In Q2, McKesson generated an operating margin profit margin of 1.1%, in line with the same quarter last year. This indicates the company's overall cost structure has been relatively stable. Earnings Per Share We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable. McKesson's EPS grew at an astounding 18.3% compounded annual growth rate over the last five years, higher than its 10.3% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded. Diving into the nuances of McKesson's earnings can give us a better understanding of its performance. As we mentioned earlier, McKesson's operating margin was flat this quarter but expanded by 3.3 percentage points over the last five years. On top of that, its share count shrank by 23.1%. These are positive signs for shareholders because improving profitability and share buybacks turbocharge EPS growth relative to revenue growth. In Q2, McKesson reported adjusted EPS at $8.26, up from $7.88 in the same quarter last year. This print beat analysts' estimates by 1.4%. Over the next 12 months, Wall Street expects McKesson's full-year EPS of $33.48 to grow 15.5%. Key Takeaways from McKesson's Q2 Results It was good to see McKesson narrowly top analysts' revenue and EPS expectations this quarter. The market seemed to be hoping for more, and the stock traded down 1.8% to $692 immediately following the results. So do we think McKesson is an attractive buy at the current price? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
28 minutes ago
- Yahoo
Yukon First Nation to oppose all new mining claims on its territory during planning
A Yukon First Nation says it will oppose any new mining claims on its traditional territory as it begins a regional land-use planning process with the territory's government. The First Nation of Na-Cho Nyak Dun says in a post on Facebook that it is issuing a notice to the mining industry that it will oppose any claim "through all available legal and political avenues." The Nation says any such claim staked during the land-use planning process are "unwelcome" and "unlawful," citing past court decisions that it says "strongly discourages staking claims in the areas" undergoing such a process. It says the Nation has adopted its own policy on mining that will govern the industry on its traditional territory while the planning process in pending. The notice comes after a catastrophic failure at an ore storage site last year at the Eagle Gold Mine, within the nation's traditional territory, that released about two-million tonnes of cyanide-laced ore and water into the environment. Yukon Energy, Mines and Resources Minister John Streicker says in a statement that the territory is aware of the notice and recommends any mining proponent to "engage with potentially affected Indigenous governments and groups as early as possible" for any project development. Streicker says the territory has recently entered into a memorandum of understanding with Na-Cho Nyak Dun to start the land-use planning process, however they haven't reached a consensus on how interim staking of mining claims should be handled while planning is taking place. "We are committed to working alongside the First Nation of Na-Cho Nyak Dun to develop a regional land use plan that considers the diverse land uses in this region," he says. "In our view, this includes maintaining a healthy environment and vibrant cultural legacy, while supporting a sustainable economy and ensuring Yukon First Nations and public priorities are appropriately reflected." Na-Cho Nyak Dun Chief Dawna Hope says in the statement that her Nation "is advising all mining companies and their financial backers that no new claims should be staked in their traditional territory to protect our planning process and our treaty rights." "We will vigorously oppose — through all possible political and legal means — any new claims staked on our territory,' Hope says. This report by The Canadian Press was first published Aug. 6, 2025. Chuck Chiang, The Canadian Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
